ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0597

TNF-α Utilizes the TWEAK/Fn-14 Axis in Human Rheumatoid Arthritis Synovial Fibroblasts

Farheen Sultan Shaikh, Anil Singh, Paul Panipinto and Salahuddin Ahmed, Washington State University, Spokane, WA

Meeting: ACR Convergence 2022

Keywords: cytokines, Fibroblasts, Synovial, rheumatoid arthritis, Therapy, alternative, Tumor necrosis factor (TNF)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: RA – Etiology and Pathogenesis Poster

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: TNF-α is a proinflammatory cytokine in rheumatoid arthritis that exerts effect through specific receptors TNFR1/2. Though it is a primary therapeutic target, there exist many low- and non-responder groups, potentially indicating novel or redundant signaling mechanisms. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK), another TNF-superfamily member, is a pleiotropic cytokine that regulates inflammatory activity, angiogenesis, cell proliferation, and tissue remodeling by binding to the fibroblast growth factor-inducible 14 (Fn-14) receptor. Though TWEAK has been characterized in other systems, the downstream effects of TWEAK and its interaction with TNF-α are not well characterized in human rheumatoid arthritis synovial fibroblasts (RASFs). This study evaluates the role of TWEAK/Fn-14 induced effector molecules in RASFs and their crosstalk with TNF-α. We also investigate the effect of Fn-14 receptor knockdown on TNF-α-mediated inflammation in human RASFs.

Methods: Human RASFs were serum-starved overnight followed by treatment with 200 ng/ml of TWEAK for 48 hours. The role of Fn-14 in TNF-α-induced inflammation was evaluated by siRNA knockdown of Fn-14 and compared to the negative control siRNA (NCsi). Human RASFs were treated with siRNA and then stimulated with TNF-α for 24 hours. Cell lysates were collected to determine the expression of the Fn-14 receptor, podoplanin, and cadherin-11 proteins using the Western blotting method. Soluble proteins MCP-1/CCL2 and RANTES/CCL5 in the conditioned media were measured by ELISA. MMP-2 and MMP-9 activities were analyzed by gelatin zymography. Invasion and migration activities were measured using a trans-well system. The experiments were performed in at least three patient cell lines and the statistical value of p< 0.05 was considered significant.

Results: TWEAK stimulation caused a 10-fold increase in MMP-2 and a 2-fold in MMP-9 activity in human RASFs. TWEAK also enhanced the release of chemokines MCP-1/CCL2 and RANTES/CCL5 in the conditioned media. Evaluation of the effect of TWEAK on functional changes showed a significant increase in the migration and invasion activity of RASFs by 15%. Knockdown of the Fn-14 receptor showed a reduction of TNF-α-induced production of chemokines- MCP1 and RANTES by 26% and 44% respectively, and of adhesion molecule- Cadherin-11 by 41% in RASFs.

Conclusion: The induction of TNF-α-related cytokines, chemokines, and migration markers by TWEAK, as well as TNF-α’s potential use of the Fn-14 receptor, suggests that the effect of TNF-α/TNFR is partially mediated by TWEAK/Fn-14 axis. Our findings in RASFs demonstrate that pharmacological inhibition of Fn-14 may provide an effective adjunct therapy to anti-TNF therapy, which may reduce the number of non-responding patients or increase efficacy for those already on an anti-TNF regimen.


Disclosures: F. Shaikh, None; A. Singh, None; P. Panipinto, None; S. Ahmed, None.

To cite this abstract in AMA style:

Shaikh F, Singh A, Panipinto P, Ahmed S. TNF-α Utilizes the TWEAK/Fn-14 Axis in Human Rheumatoid Arthritis Synovial Fibroblasts [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/tnf-%ce%b1-utilizes-the-tweak-fn-14-axis-in-human-rheumatoid-arthritis-synovial-fibroblasts/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tnf-%ce%b1-utilizes-the-tweak-fn-14-axis-in-human-rheumatoid-arthritis-synovial-fibroblasts/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology